CRO Services
Participate In a Study
About Us
Careers
Contact
FR
CRO Services
Participate In a Study
About Us
Careers
Contact
FR
Test
Post navigation
Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
